While bluebird bio Inc. is gearing up to launch its first commercial drug – the gene therapy Zynteglo for transfusion-dependent beta-thalassemia (TDT) – shortly in Europe, the company is building out its pipeline with a focus on immuno-oncology and rare diseases.
Bluebird held an analyst day in New York City on 9 May to highlight commercial plans for Zynteglo (previously LentiGlobin)...








